Collegium Pharmaceutical, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Collegium Pharmaceutical, Inc. (COLL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.40% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-02-27
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.50%, a 66.67% decline year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 1.50%, a 42.31% decline year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-03-31 was 2.60%, a 0.00% change year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-03-31 was 2.60%, a 23.81% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.40%.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.70%, a 46.15% decline from fiscal 2020.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 1.30%, a 45.83% decline from fiscal 2019.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.40%, a 7.69% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2024-12-31 | 4.40% 10-K · filed 2025-02-27 | |||
| 2021-12-31 | 0.70% 10-K · filed 2024-02-22 | |||
| 2021-09-30 | 0.70% 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | 0.70% 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | 0.50% 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | 1.30% 10-K · filed 2023-02-23 | |||
| 2020-09-30 | 1.30% 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 1.30% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 1.50% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 2.40% 10-K · filed 2022-02-24 | |||
| 2019-09-30 | 2.40% 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 2.60% 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | 2.60% 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 2.60% 10-K · filed 2021-02-25 | |||
| 2018-09-30 | 2.60% 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | 2.60% 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | 2.60% 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | 2.00% 10-K · filed 2020-02-27 | |||
| 2017-09-30 | 2.00% 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | 2.00% 10-Q · filed 2018-08-08 | |||
| 2017-03-31 | 2.10% 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | 1.50% 10-K · filed 2019-02-27 | |||
| 2016-09-30 | 1.50% 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | 1.50% 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | 1.60% 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | 1.70% 10-K · filed 2018-03-07 | |||
| 2015-09-30 | 1.70% 10-Q · filed 2016-11-10 | |||
| 2015-06-30 | 1.70% 10-Q · filed 2016-08-11 | |||
| 2015-03-31 | 1.60% 10-Q · filed 2016-05-11 | |||
| 2014-12-31 | 1.80% 10-K · filed 2017-03-10 | |||
| 2014-09-30 | 1.80% 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |